^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Oligodendroglioma

    Related cancers:
    Apply
    SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma (NCT04923126)
    Phase 1/2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/21/2021
    Primary completion :
    06/01/2031
    Completion :
    06/01/2031
    BRAF • NF1 • PTPN11 • MYBL1
    |
    BRAF mutation
    |
    Gomekli (mirdametinib)
    Study of Olutasidenib and Temozolomide in HGG (NCT06161974)
    Phase 2
    Rigel Pharmaceuticals
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/01/2025
    Primary completion :
    06/01/2029
    Completion :
    06/01/2035
    IDH1
    |
    IDH1 mutation
    |
    temozolomide • Rezlidhia (olutasidenib)
    Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (M23-385) (NCT05599984)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/05/2022
    Primary completion :
    10/01/2025
    Completion :
    05/01/2027
    EGFR • SEZ6
    |
    EGFR mutation • IDH wild-type
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (NCT04295759)
    Phase 1
    Pediatric Brain Tumor Consortium
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    07/27/2020
    Primary completion :
    12/31/2023
    Completion :
    12/01/2024
    HER-2 • CD4 • ADAM10
    |
    aderbasib (INCB7839)
    A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations (NCT05503797)
    Phase 2
    Fore Biotherapeutics
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/21/2023
    Primary completion :
    06/27/2025
    Completion :
    08/28/2026
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    plixorafenib (FORE-8394) • Tybost (cobicistat)
    Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors (NCT05429502)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    12/27/2022
    Primary completion :
    10/15/2027
    Completion :
    01/28/2028
    MYCN • SMARCB1
    |
    IDH wild-type
    |
    temozolomide • Kisqali (ribociclib) • topotecan
    All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma (NCT05345002)
    Phase 2
    Stephen Bagley, MD, MSCE
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    11/16/2022
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    IDH1 • IDH2 • MGMT
    |
    IDH1 mutation • IDH2 mutation
    |
    Zynyz (retifanlimab-dlwr)
    Seizure Treatment in Glioma (STING) (NCT03048084)
    Phase 4
    Leiden University Medical Center
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    02/01/2018
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    IDH1
    |
    IDH1 mutation • IDH wild-type
    Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors (PNOC028) (NCT05887882)
    Phase 1
    Sabine Mueller, MD, PhD
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    05/31/2024
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    TGFB1 • TGFBI
    Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma (CL1-95032-005) (NCT05484622)
    Phase 1
    Institut de Recherches Internationales Servier
    Recruiting
    Last update posted :
    01/14/2025
    Initiation :
    01/20/2023
    Primary completion :
    03/31/2025
    Completion :
    08/30/2027
    IDH1 • ATRX
    |
    IDH1 R132
    |
    Keytruda (pembrolizumab) • Voranigo (vorasidenib)
    Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype (NCT02658279)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    12/06/2024
    Initiation :
    01/22/2016
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    MSI • POLE • MSH6 • MSH2 • POLD1
    |
    Keytruda (pembrolizumab)